- Home
- GLPG vs OPRA Comparison
GLPG vs OPRA Comparison
Compare GLPG & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | OPRA |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | Belgium | Norway |
| Employees | 452 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLPG | OPRA |
|---|---|---|
| Price | $27.75 | $18.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $36.50 | $21.50 |
| AVG Volume (30 Days) | 129.6K | ★ 602.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | N/A | $15.34 |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.97 | $11.71 |
| 52 Week High | $37.78 | $21.06 |
Technical Indicators
Market Signals| Indicator | GLPG | OPRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 59.67 |
| Support Level | N/A | $15.55 |
| Resistance Level | $34.04 | $19.24 |
| Average True Range (ATR) | 0.56 | 0.76 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 25.33 | 62.01 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.